LEISHMANIASIS
Diagnosis,
Diagnostics, Immunodiagnosis & Immunodiagnostics:
6766.
Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra
WO,Gollob KJ, Carvalho EM.Up-regulation of Th1-type responses in mucosal
leishmaniasis patients.Infect Immun 2002
Dec;70(12):6734-40
6767.
Bosch RJ, Rodrigo AB, Sanchez P, de Galvez MV, Herrera E. Presence of
Leishmania organisms in specific and non-specific skin lesions in HIV-infected
individuals with visceral leishmaniasis. Int J Dermatol
2002 Oct;41(10):670-5
Pathogenesis:
6768.
Rodrigues EH, Felinto de Brito ME, Mendonca MG, Werkhauser RP, Coutinho
EM, Souza WV, Militao de Albuquerque Mde F, Jardim ML, Abath FG. Evaluation of
PCR for diagnosis of American cutaneous leishmaniasis in an area of endemicity
in northeastern Brazil. J Clin Microbiol 2002
Oct;40(10):3572-6
6769.
Vilela RB, Bordin JO, Chiba AK, Castelo A, Barbosa MC. RBC-associated IgG
in patients with visceral leishmaniasis (kala-azar): a prospective analysis.
Transfusion 2002 Nov;42(11):1442-7
Therapy:
6770.
Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty
P, Gastaut JA, Costagliola D, Rosenthal E;
French Hospital Database on HIV Clinical Epidemiologic Group. Impact of
highly active antiretroviral therapy on the incidence of visceral leishmaniasis
in a French cohort of patients infected with human immunodeficiency virus. J
Infect Dis 2002 Nov
1;186(9):1366-70
6771.
Jacobs S. An oral drug for leishmaniasis. N Engl J Med 2002 Nov 28;347(22):1737-8
Back |